The P-II (EMBOLD) clinical trial evaluates the safety & efficacy of ATA188 vs PBO in patients (n=103) with non-active progressive multiple sclerosis for duration of 12mos.
The study failed to meet its 1EP of confirmed disability improvement (CDI)by expanded disability status scale (EDSS) at 13mos. vs PBO as a 6% of disability improvement was measured in the P-II trial vs 33% in the P-I trial whereas a 16% rate for CDI was seen which was greater than the expected rate of 4-6%
The upcoming events regarding the P-II (EMBOLD) clinical trial will be determined by the company after actively reviewing the data generated. Atara will also focus on resources & expense reductions in order to extend the cash runway beyond Q3’25
Ref: Businesswire | Image: Atara Biotherapeutics
Related Posts:- Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
